Pricing Log in Create free account
Saturday 17 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Moderna, Inc. (MRNA) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Sep 30, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 27, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: no comparison — the Item was not found
P2I1A: no material changes, the filing says
8-K Jul 31, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K May 6, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 1, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 3, 2026 1.01 Entry into a material definitive agreement
10-K Dec 31, 2025 1: 82 added · 111 removed · 129 modified
1A: 28 added · 26 removed · 131 modified
7: 27 added · 29 removed · 38 modified
8-K Feb 13, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 3, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 5, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 19, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Nov 20, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 12, 2025 5.07 Submission of matters to a vote of security holders
10-Q Sep 30, 2025
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.